Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)
- First Posted Date
- 2010-08-18
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 315
- Registration Number
- NCT01183858
A Study of RO4917838 With Rosuvastatin in Healthy Volunteers
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01183585
A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3
- Registration Number
- NCT01183598
A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1
Phase 1
Completed
- Conditions
- Hepatitis C, Chronic, Healthy Volunteer
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 82
- Registration Number
- NCT01181024
A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 54
- Registration Number
- NCT01181609
A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.
Phase 4
Withdrawn
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01179594
A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2018-10-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 681
- Registration Number
- NCT01178086
- Locations
- 🇩🇪
PIOH PD Dr. R. Schnell - Dr. H. Schulz - Dr. M. Hellmann, Frechen, Germany
A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy
Phase 2
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-08-03
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT01174563
- Locations
- 🇮🇱
Haemek Hospital; Oncology, Afula, Israel
🇮🇱Barzilai; Oncology, Ashkelon, Israel
🇮🇱Meir Medical Center; Oncology, Kfar-Saba, Israel
A Pharmacokinetic Study on Co-administration of Tamiflu (Oseltamivir) and Rimantadine in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2010-07-30
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT01172847
A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.
Phase 3
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Drug: Fluoropyrimidine-based Chemotherapy
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 168
- Registration Number
- NCT01169558
© Copyright 2025. All Rights Reserved by MedPath